---
title: "Opdivo (nivolumab), all indications: Safety questions"
description: "Safety questions on Opdivo (nivolumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings, Safety management, and Monitoring. Questions: What immune-mediated side effects can Opdivo cause? How are Opdivo immune-mediated side effects managed? What lab monitoring does Opdivo require? Does Opdivo have contraindications? 2 further questions follow. 6 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/opdivo/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Opdivo (nivolumab), all indications: Safety questions

Manufacturer: Bristol-Myers Squibb Company  
Prescribing information: [Opdivo](https://packageinserts.bms.com/pi/pi_opdivo.pdf)  
Indication pages: [Metastatic non-small cell lung cancer](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer)

## Warnings

<a id="opdivo-immune-mediated-reactions"></a>

### What immune-mediated side effects can Opdivo cause?

> “•	 Immune-Mediated Adverse Reactions:  (5.1)
> 	• Immune-mediated adverse reactions, which may be severe or fatal, can occur in 
> any organ system or tissue, including the following: immune-mediated pneumonitis, 
> immune-mediated colitis, immune-mediated hepatitis and hepatotoxicity, immune-
> mediated endocrinopathies, immune-mediated dermatologic adverse reactions, and 
> immune-mediated nephritis and renal dysfunction.”

Source: [OPDIVO: OPDIVO, page 2, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=2)

> “Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. While immune-mediated adverse reactions usually manifest during treatment, they can also occur after discontinuation of OPDIVO QVANTIG, OPDIVO, or YERVOY.”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=Immune%2Dmediated%20adverse%20reactions%2C%20which%20may,OPDIVO%20QVANTIG%2C%20OPDIVO%2C%20or%20YERVOY.)

<a id="opdivo-contraindications"></a>

### Does Opdivo have contraindications?

> “CONTRAINDICATIONS
> None.”

Source: [OPDIVO: OPDIVO, page 7, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=7)

> “CONTRAINDICATIONS
> None.”

Source: [OPDIVO: OPDIVO Qvantig, page 6, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo-qvantig.pdf#page=6)

Note: The first passage is from the Opdivo (intravenous) Prescribing Information and the second from the Opdivo Qvantig Prescribing Information.

<a id="opdivo-warnings"></a>

### What are the warnings and precautions for Opdivo?

> “•	 Infusion-related reactions:  Interrupt, slow the rate of infusion, or permanently discontinue 
> OPDIVO based on severity of reaction. (5.2)
> •	 Complications of allogeneic HSCT:  Fatal and other serious complications can occur 
> in patients who receive allogeneic HSCT before or after being treated with a PD-1/PD-L1 
> blocking antibody. (5.3)
> •	 Embryo-Fetal toxicity:  Can cause fetal harm. Advise females of reproductive potential of 
> potential risk to a fetus and to use effective contraception. (5.4, 8.1, 8.3)
> •	 Treatment of patients with multiple myeloma with a PD-1 or PD-L1 blocking antibody in 
> combination with a thalidomide analogue plus dexamethasone is not recommended 
> outside of controlled clinical trials. (5.5)”

Source: [OPDIVO: OPDIVO, page 2, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=2)

Note: Immune-mediated adverse reactions (5.1), the first warning, are covered under the question on immune-mediated side effects.

<a id="opdivo-stem-cell-transplant"></a>

### Is Opdivo safe before or after a stem cell transplant?

> “Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with OPDIVO QVANTIG or OPDIVO or YERVOY. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between OPDIVO QVANTIG or OPDIVO or YERVOY and allogeneic HSCT.
>
> Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with OPDIVO QVANTIG, OPDIVO, and YERVOY prior to or after an allogeneic HSCT.”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=Fatal%20and%20other%20serious%20complications,or%20after%20an%20allogeneic%20HSCT.)

## Safety management

<a id="opdivo-immune-mediated-management"></a>

### How are Opdivo immune-mediated side effects managed?

> “Withhold or permanently discontinue OPDIVO QVANTIG, OPDIVO, and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). In general, if OPDIVO QVANTIG, OPDIVO or YERVOY interruption or discontinuation is required, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy. Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below.”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=Withhold%20or%20permanently%20discontinue%20OPDIVO,dermatologic%20reactions%29%20are%20discussed%20below.)

## Monitoring

<a id="opdivo-monitoring"></a>

### What lab monitoring does Opdivo require?

> “Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and periodically during treatment with OPDIVO QVANTIG, OPDIVO and before each dose of YERVOY.”

Source: [OPDIVO: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC, captured 2026-11-13](https://www.opdivohcp.com/first-line-mnsclc/efficacy#:~:text=Evaluate%20clinical%20chemistries%20including%20liver,before%20each%20dose%20of%20YERVOY.)

> “• Monitor for early identification and management. Evaluate liver enzymes, creatinine, 
> and thyroid function at baseline and periodically during treatment.”

Source: [OPDIVO: OPDIVO, page 2, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=2)

## Related pages
- [Medical information: Opdivo (nivolumab): All indications](https://www.evicenter.com/medical-information/opdivo)
- [Indication](https://www.evicenter.com/medical-information/opdivo/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/opdivo/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/opdivo/specific-populations)
- [Storage and supply](https://www.evicenter.com/medical-information/opdivo/storage-and-supply)
